针对 ALK 重排非小细胞肺癌的新治疗策略。
New strategies for treatment of ALK-rearranged non-small cell lung cancers.
机构信息
Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.
出版信息
Clin Cancer Res. 2011 Dec 1;17(23):7213-8. doi: 10.1158/1078-0432.CCR-11-1404. Epub 2011 Oct 18.
Abstract
The identification of oncogenic alterations in subsets of patients with non-small cell lung cancer (NSCLC) is transforming clinical care. Genomic rearrangements in anaplastic lymphoma kinase (ALK) are detected in 3% to 7% of patients with NSCLC. The ALK tyrosine kinase inhibitor crizotinib has demonstrated clinical efficacy in ALK-rearranged NSCLC patients and was recently approved by the U.S. Food and Drug Administration. Crizotinib is currently under additional phase III clinical development as both initial and second-line therapy for advanced ALK-rearranged NSCLC. However, new challenges in the diagnosis and treatment of this subset of NSCLC have emerged, including the need to determine the most effective means of diagnosing ALK-rearranged NSCLC and the emergence of acquired drug resistance to crizotinib. In this review, we discuss current strategies for treatment and diagnosis, as well as the current knowledge about mechanisms of acquired resistance to crizotinib. Finally, we discuss the strategies that are underway to clinically overcome acquired drug resistance.
摘要
在非小细胞肺癌（NSCLC）的某些患者亚群中，鉴定致癌改变正在改变临床护理。在 3%至 7%的 NSCLC 患者中可检测到间变性淋巴瘤激酶（ALK）的基因组重排。ALK 酪氨酸激酶抑制剂克唑替尼在 ALK 重排的 NSCLC 患者中显示出临床疗效，最近已被美国食品和药物管理局批准。克唑替尼目前正在进行额外的 III 期临床开发，作为晚期 ALK 重排 NSCLC 的一线和二线治疗。然而，在这一组 NSCLC 的诊断和治疗中出现了新的挑战，包括需要确定诊断 ALK 重排 NSCLC 的最有效方法，以及对克唑替尼获得性耐药的出现。在这篇综述中，我们讨论了当前的治疗和诊断策略，以及关于克唑替尼获得性耐药机制的现有知识。最后，我们讨论了正在进行的克服获得性药物耐药性的策略。
相似文献
1
New strategies for treatment of ALK-rearranged non-small cell lung cancers.针对 ALK 重排非小细胞肺癌的新治疗策略。
Clin Cancer Res. 2011 Dec 1;17(23):7213-8. doi: 10.1158/1078-0432.CCR-11-1404. Epub 2011 Oct 18.
2
Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.ALK重排的晚期非小细胞肺癌（NSCLC）对克唑替尼的耐药性：机制、治疗策略及新的靶向治疗方法
Curr Clin Pharmacol. 2016;11(2):77-87. doi: 10.2174/1574884711666160502124134.
3
ALK inhibitors in the treatment of advanced NSCLC.ALK 抑制剂治疗晚期 NSCLC。
Cancer Treat Rev. 2014 Mar;40(2):300-6. doi: 10.1016/j.ctrv.2013.07.002. Epub 2013 Aug 7.
4
Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.克唑替尼：一种新型的、同类首创的多靶点酪氨酸激酶抑制剂，用于治疗间变性淋巴瘤激酶重排的非小细胞肺癌及其他疾病。
Drug Des Devel Ther. 2011;5:471-85. doi: 10.2147/DDDT.S19045. Epub 2011 Nov 23.
5
Treatment and detection of ALK-rearranged NSCLC.ALK 重排非小细胞肺癌的治疗与检测。
Lung Cancer. 2013 Aug;81(2):145-54. doi: 10.1016/j.lungcan.2013.03.017. Epub 2013 Jun 12.
6
Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions.ALK 重排非小细胞肺癌的治疗：最新进展与未来方向。
Drugs. 2015 Jul;75(10):1059-70. doi: 10.1007/s40265-015-0415-9.
7
Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.用于非小细胞肺癌的I期和II期临床试验中的间变性淋巴瘤激酶抑制剂
Expert Opin Investig Drugs. 2017 Jun;26(6):713-722. doi: 10.1080/13543784.2017.1324572. Epub 2017 May 18.
8
ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?ALK抑制剂：治疗ALK阳性非小细胞肺癌患者的最佳方法是什么？
Clin Lung Cancer. 2014 Sep;15(5):313-9. doi: 10.1016/j.cllc.2014.05.001. Epub 2014 Jun 2.
9
Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.克唑替尼治疗间变性淋巴瘤激酶重排的非小细胞肺癌：分子靶向治疗在肿瘤学中开启第二个十年的成功典范。
Oncologist. 2012;17(11):1351-75. doi: 10.1634/theoncologist.2012-0311. Epub 2012 Sep 18.
10
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.ALK 抑制剂色瑞替尼克服非小细胞肺癌的克唑替尼耐药性。
Cancer Discov. 2014 Jun;4(6):662-673. doi: 10.1158/2159-8290.CD-13-0846. Epub 2014 Mar 27.
引用本文的文献
1
STK3-ALK, a Novel ALK Rearrangement in Non-Small Cell Lung Cancer With Sensitivity to Tyrosine Kinase Inhibitors: A Case Report.STK3-ALK，一种对酪氨酸激酶抑制剂敏感的非小细胞肺癌中的新型ALK重排：病例报告
Front Oncol. 2021 Aug 19;11:700341. doi: 10.3389/fonc.2021.700341. eCollection 2021.
2
Identification of a potent kinase inhibitor targeting EML4-ALK fusion protein in non-small cell lung cancer.在非小细胞肺癌中鉴定一种靶向EML4-ALK融合蛋白的强效激酶抑制剂。
Medchemcomm. 2017 Aug 25;8(10):1914-1918. doi: 10.1039/c7md00305f. eCollection 2017 Oct 1.
3
AXL-GAS6 expression can predict for adverse prognosis in non-small cell lung cancer with brain metastases.AXL-GAS6表达可预测非小细胞肺癌脑转移的不良预后。
J Cancer Res Clin Oncol. 2017 Oct;143(10):1947-1957. doi: 10.1007/s00432-017-2408-4. Epub 2017 May 27.
4
Hapten-enhanced therapeutic effect in advanced stages of lung cancer by ultra-minimum incision personalized intratumoral chemoimmunotherapy therapy.通过超微小切口个性化瘤内化学免疫疗法实现的半抗原增强对晚期肺癌的治疗效果。
Lung Cancer (Auckl). 2015 Jan 7;6:1-11. doi: 10.2147/LCTT.S70679. eCollection 2015.
5
Role of FNAC, fluid specimens, and cell blocks for cytological diagnosis of lung cancer in the present era.细针穿刺抽吸活检（FNAC）、体液标本及细胞块在当代肺癌细胞学诊断中的作用
J Cytol. 2015 Oct-Dec;32(4):217-22. doi: 10.4103/0970-9371.171219.
6
Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer.克唑替尼作为先前接受过治疗的间变性淋巴瘤激酶重排非小细胞肺癌患者的靶向个体化替代治疗药物。
Drug Des Devel Ther. 2015 Oct 3;9:5491-7. doi: 10.2147/DDDT.S91988. eCollection 2015.
7
The relevance of external quality assessment for molecular testing for ALK positive non-small cell lung cancer: results from two pilot rounds show room for optimization.间变性淋巴瘤激酶（ALK）阳性非小细胞肺癌分子检测的外部质量评估的相关性：两轮试点结果显示仍有优化空间。
PLoS One. 2014 Nov 11;9(11):e112159. doi: 10.1371/journal.pone.0112159. eCollection 2014.
8
Implementing the new IASLC/ATS/ERS classification of lung adenocarcinomas: results from international and Chinese cohorts.实施国际肺癌研究协会/美国胸科学会/欧洲呼吸学会肺癌腺癌新分类：国际和中国队列研究结果
J Thorac Dis. 2014 Oct;6(Suppl 5):S568-80. doi: 10.3978/j.issn.2072-1439.2014.09.13.
9
MET gene copy number predicts worse overall survival in patients with non-small cell lung cancer (NSCLC); a systematic review and meta-analysis.MET基因拷贝数可预测非小细胞肺癌（NSCLC）患者更差的总生存期；一项系统评价与Meta分析。
PLoS One. 2014 Sep 18;9(9):e107677. doi: 10.1371/journal.pone.0107677. eCollection 2014.
10
Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent c-Met/ALK Multikinase Inhibitory Activities.新型2,4-二芳基氨基嘧啶类似物（DAAP类似物）展现出强效的c-Met/ALK多激酶抑制活性。
ACS Med Chem Lett. 2014 Feb 8;5(4):304-8. doi: 10.1021/ml400373j. eCollection 2014 Apr 10.
本文引用的文献
1
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.一种新的 ALK 二次突变和 EGFR 信号导致对 ALK 激酶抑制剂的耐药性。
Cancer Res. 2011 Sep 15;71(18):6051-60. doi: 10.1158/0008-5472.CAN-11-1340. Epub 2011 Jul 26.
2
Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.通过新型 ALK 酪氨酸激酶抑制剂的开发揭示 ALK 驱动型癌症的见解。
Cancer Res. 2011 Jul 15;71(14):4920-31. doi: 10.1158/0008-5472.CAN-10-3879. Epub 2011 May 25.
3
Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression.检测非小细胞肺癌中的 ALK 基因重排：荧光原位杂交与显色原位杂交的比较及与 ALK 蛋白表达的相关性。
J Thorac Oncol. 2011 Aug;6(8):1359-66. doi: 10.1097/JTO.0b013e31821cfc73.
4
CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.CH5424802，一种选择性的 ALK 抑制剂，能够阻断耐药性的守门员突变体。
Cancer Cell. 2011 May 17;19(5):679-90. doi: 10.1016/j.ccr.2011.04.004.
5
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.克服携带融合癌基因 EML4-ALK 的非小细胞肺癌对克唑替尼耐药的治疗策略。
Proc Natl Acad Sci U S A. 2011 May 3;108(18):7535-40. doi: 10.1073/pnas.1019559108. Epub 2011 Apr 18.
6
Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer.ERK-BIM 和 STAT3-survivin 信号通路在 ALK 抑制剂诱导 EML4-ALK 阳性肺癌细胞凋亡中的作用。
Clin Cancer Res. 2011 Apr 15;17(8):2140-8. doi: 10.1158/1078-0432.CCR-10-2798. Epub 2011 Mar 17.
7
Treatment of lung cancer with an ALK inhibitor after EML4-ALK fusion gene detection using endobronchial ultrasound-guided transbronchial needle aspiration.使用支气管内超声引导下经支气管针吸活检检测到EML4-ALK融合基因后，用ALK抑制剂治疗肺癌。
J Thorac Oncol. 2010 Dec;5(12):2041-3. doi: 10.1097/JTO.0b013e3181f77b58.
8
Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.优化检测存在间变性淋巴瘤激酶（ALK）基因重排的肺癌患者，这些患者可能适合接受 ALK 抑制剂治疗。
Clin Cancer Res. 2010 Nov 15;16(22):5581-90. doi: 10.1158/1078-0432.CCR-10-0851. Epub 2010 Nov 9.
9
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.神经母细胞瘤相关的 F1174L ALK 突变导致 ALK 易位癌症对 ALK 激酶抑制剂产生耐药性。
Cancer Res. 2010 Dec 15;70(24):10038-43. doi: 10.1158/0008-5472.CAN-10-2956. Epub 2010 Oct 28.
10
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.非小细胞肺癌中导致对 ALK 抑制剂耐药的 EML4-ALK 突变。
N Engl J Med. 2010 Oct 28;363(18):1734-9. doi: 10.1056/NEJMoa1007478.
Zotero 插件